(RTTNews) – Today’s dose brings you news on the progress of BIOpharmaceutical ARCA in its COVID-19 drug candidate, the upcoming AC Immune milestones, the November catalyst for BrainStorm Cell, the Bristol-Myers/Pfizer Eliquis patent resolution and phase I positive knowledge of Novavax’s COVID-19 vaccine trial.
Read…
1. Biopharmaceutical ARK to AB201 for COVID-19
ARCA Biopharma Inc. (ABIO) plans to apply for a new experimental drug for AB201 as a possible remedy for COVID-19 in the third quarter of this year to seek approval to launch a Phase II trial.
Gencaro, the company’s leading experimental drug, is being developed for the prevention of atrial fibrillation/atrial flutter in a population of genetically modified central fault. The launch of a Phase III trial at Gencaro, called PRECISION-AF, is suspended due to the ongoing COVID-19 pandemic.
Enlistment in the PRECISION-AF trial can begin in 2021, according to ARCA.
ABIO closed Wednesday’s consultation at $6.77, 0.15% less.
2. AC Immune will need to report knowledge of Alzheimer’s 2S20 trials
The company’s main anti-Tau antibody is Semorinemab, developed in collaboration with Roche’s Genetech. Semorinemab is in a Phase II trial for the treatment of patients with mild prodromic Alzheimer’s disease. The greatest knowledge for this test is expected to be in the current part of 2020.
Just last month, the company completed its ACI-35,030 Alzheimer’s Tau vaccine in a phase 1b/2a clinical trial.
ACIU closed Wednesday’s consultation at $6.57, 6.81% less.
3. BrainStorm prepares to reveal the effects of the ALS trial
A phase III pivotal trial investigating NurOwn in amyotrophic lateral sclerosis is underway, with topline data readout expected by the end of November this year.
A Phase II clinical trial of NurOwn is underway in progressive sclerosis and is expected to complete the dose by the end of 2020.
The company is making plans for a Phase II test trial of NurOwn in Alzheimer’s disease at several EA centers in the Netherlands and France.
BCLI closed Wednesday’s consultation at $13.11, down 2.09 percent.
In a lawsuit filed through Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE) in opposition to Sigmapharm Laboratories LLC, Unichem Laboratories Ltd.et Sunshine Lake Pharma Co.Ltd. on an anticoagulant Eliquis, the Tribunal in favor of the two main pharmaceutical companies.
Pfizer and Bristol-Myers Squibb have a global collaboration to expand and market Eliquis that was learned through Bristol-Myers.
Sigmapharm Labs, Unichem Labs and Sunshine Lake are among the FDA-approved generic drug brands for their generic versions of Eliquis.
According to Bristol-Myers and Pfizer, the key composition of the Eliquis curtain patent in the United States does not expire until 2031. Therefore, now that the Court has ruled in favor of Pfizer and Bristol-Myers, the 3 generic brands recently involved in caseArray will not release generic versions of Eliquis until 2031.
The FDA was generic versions of Eliquis, manufactured through Mylan and Micro Labs last December, which marked the first generic versions of the drug.
In the first quarter of 2020, Eliquis generated sales of $2.64 billion for Bristol-Myers and $1.30 billion for Pfizer.
BMY closed Wednesday’s operations at $59.69, an increase of 0.37 percent. Outside of business hours, inventory rose 4.21% to $62.20.
5. Novavax with positive effects from the COVID-19 Phase I vaccine trial
In Phase I, which evaluated NVX-CoV2373 with adjuvant with Matrix-M, the vaccine candidate was well tolerated and obtained physically powerful numerically impressive antibody responses than those observed in human convalescent serums.
“All subjects developed anti-peak IgG antibodies after a single dose of the vaccine, many of them also had antibody responses that neutralized the wild-type virus, and after dose 2, one hundred percent of participants developed antibody responses that neutralized the wild-type virus virus,” the company said.
The trial was funded through the Coalition for Epidemic Preparedness Innovations (CEPI) and was conducted at two sites in Australia.
NVAX closed on Wednesday at $173.49, an increase of 10.38%.
Biofrontera AG (BFRA) closed on Wednesday at $26.80, an increase of 378.57%.
Alimera Sciences Inc. (ALIM) closed Wednesday at $6.98, an increase of 27.84%.
Iteos Therapeutics Inc. (ITOS) closed On Wednesday at $28.88, an increase of 17.21%.
Alterity Therapeutics Limited (ATHE) closed Wednesday’s consultation at $2.91, down 15.16%.
Inozyme Pharma Inc. (INZY) closed Wednesday’s consultation at $22.43, up 9.30% less.